Patients interested in weight management can also explore our Weight Loss Quiz or learn more about medical weight loss consultations
Based on evidence from completed cardiovascular and kidney outcome trials, organizations like the American Diabetes Association (ADA), the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE), the American College of Cardiology (ACC), and Kidney Disease: Improving Global Outcomes (KDIGO) note the glycemic, weight, and organ protective benefits of GLP-1 RAs
GLP-1 controls appetite and blood sugar, while balanced hormones restore metabolic function and energy
The strongest evidence layer in this stack
Studies examining receptor binding have shown that Retatrutide demonstrates strong activity at the human GIP receptor while maintaining measurable activity at both GLP-1 and glucagon receptors, creating a balanced activation profile that allows researchers to explore receptor crosstalk and multi-pathway metabolic signaling [2]